1. Home
  2. COSM vs JSPR Comparison

COSM vs JSPR Comparison

Compare COSM & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cosmos Health Inc.

COSM

Cosmos Health Inc.

HOLD

Current Price

$0.25

Market Cap

15.8M

Sector

Health Care

ML Signal

HOLD

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.49

Market Cap

14.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COSM
JSPR
Founded
2009
2018
Country
United States
United States
Employees
N/A
22
Industry
Other Pharmaceuticals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.8M
14.9M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
COSM
JSPR
Price
$0.25
$0.49
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
1.2M
566.3K
Earning Date
04-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
46.15
N/A
EPS
N/A
N/A
Revenue
$65,271,815.00
N/A
Revenue This Year
$54.08
N/A
Revenue Next Year
$32.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.93
N/A
52 Week Low
$0.25
$0.43
52 Week High
$1.32
$7.19

Technical Indicators

Market Signals
Indicator
COSM
JSPR
Relative Strength Index (RSI) 38.07 25.07
Support Level $0.25 N/A
Resistance Level $0.41 $1.06
Average True Range (ATR) 0.02 0.11
MACD 0.00 -0.04
Stochastic Oscillator 4.25 10.26

Price Performance

Historical Comparison
COSM
JSPR

About COSM Cosmos Health Inc.

Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: